European Forecasts Hint at 2027 GPS Approval

Sellas Life Sciences Group (SLS) is under scrutiny following BlackRock's disclosure of a 7.9% stake. European health-tech assessments propose potential approval or registration for Sellas's leukemia immunotherapy, GPS, in November 2027 (Austria) and April 2027 (Netherlands), though with inherent uncertainty. The Phase 3 Regal trial, targeting WT1 protein in acute myeloid leukemia (AML) patients, is approaching its primary endpoint trigger: the 80th death across treatment groups, with 78 events noted as of May 11. Positive results could support a U.S. FDA filing, while Sellas remains blinded to current outcomes.

Further catalysts for Sellas include its selective CDK9 inhibitor, SLS009 (Tambiciclib). Topline results from a Phase 2 study in AML patients are anticipated in the fourth quarter. The company also recently presented preclinical findings on SLS009's activity in pancreatic cancer models. Despite a recent dip to 'neutral' sentiment on Stocktwits, SLS stock has seen a remarkable 223% year-to-date surge, driven by these developments.